How will the latest modifications to the CG189 NICE guidelines for obesity management likely impact clinical care?  

作　　者：Thomas M.Barber 

机构地区：[1]Warwickshire Institute for the Study of Diabetes,Endocrinology and Metabolism,University Hospitals Coventry and Warwickshire,Clifford Bridge Road,Coventry,UK [2]Division of Biomedical Sciences,Clinical Sciences Research Laboratories,Warwick Medical School,University of Warwick,Coventry,UK

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第3期413-416,共4页肝胆外科与营养（英文）

摘　　要：Based on the 2019 Health Survey for England,nearly two thirds of the adult population and one third of children(aged 2-15 years)are either overweight or obese(1).In England,obesity affects 28%of adults,20%of boys and 13%of girls(1).Obesity is a chronic,often life-long disease that associates with>50 weight-related conditions,most notably type 2 diabetes mellitus(T2D),and other dysmetabolic conditions that contribute towards the metabolic syndrome and many other conditions that impact on nearly every aspect of physiology and mental functioning(2).Obesity has a huge economic burden,with government estimates indicating the current costs of obesity in the UK at£6.1 billion to the National Health Service(NHS),and£27 billion to wider society(1).Despite this,obesity remains fundamentally misunderstood and neglected.This is reflected by woeful under-funding of management strategies for obesity(despite many of these being highly efficacious),guidelines that place time-limitations on potentially effective therapies(with possible negative outcomes that stem from subsequent weight re-gain),and a prevailing fog of obesity-related stigma that seems to pervade its way throughout society like a contagion.

关 键 词：OBESITY COMPASSION AWARENESS ADAPTABILITY 

分 类 号：R589.2[医药卫生—内分泌]